NASDAQ:ODT - Odonate Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.77 -0.18 (-0.75 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$23.95
Today's Range$23.11 - $24.46
52-Week Range$15.15 - $32.00
Volume15,100 shs
Average Volume54,065 shs
Market Capitalization$643.97 million
P/E Ratio-10.29
Dividend YieldN/A
BetaN/A
Odonate Therapeutics logoOdonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Debt-to-Equity RatioN/A
Current Ratio20.52
Quick Ratio20.52

Price-To-Earnings

Trailing P/E Ratio-10.29
Forward P/E Ratio-6.97
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.29 per share
Price / Book3.26

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees60
Outstanding Shares26,890,000
Market Cap$643.97

The Truth About Cryptocurrencies

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) released its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.16. View Odonate Therapeutics' Earnings History.

What price target have analysts set for ODT?

3 brokers have issued 12-month price objectives for Odonate Therapeutics' shares. Their predictions range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' stock price to reach $33.50 in the next year. This suggests a possible upside of 40.9% from the stock's current price. View Analyst Ratings for Odonate Therapeutics.

What is the consensus analysts' recommendation for Odonate Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Odonate Therapeutics' key competitors?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the folowing people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 51)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 64)
  • Mr. John G. Lemkey, Chief Financial Officer (Age 37)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 42)
  • Ms. Nicole H. Gollaher J.D., VP of Legal Affairs (Age 49)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

When did Odonate Therapeutics' lock-up period expire?

Odonate Therapeutics' lock-up period expired on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its initial public offering on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Has Odonate Therapeutics been receiving favorable news coverage?

News coverage about ODT stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Odonate Therapeutics earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media stories about the company an impact score of 45.84 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $23.77.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $643.97 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]


MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.